AnaptysBio, Inc. (ANAB)

NASDAQ: ANAB · Real-Time Price · USD
20.59
+0.26 (1.28%)
At close: Sep 2, 2025, 4:00 PM
20.61
+0.02 (0.10%)
After-hours: Sep 2, 2025, 4:39 PM EDT
1.28%
Market Cap576.46M
Revenue (ttm)123.16M
Net Income (ttm)-132.59M
Shares Out 28.00M
EPS (ttm)-4.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume177,526
Open20.72
Previous Close20.33
Day's Range20.56 - 20.74
52-Week Range12.21 - 40.70
Beta-0.19
AnalystsBuy
Price Target48.00 (+133.12%)
Earnings DateAug 6, 2025

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2017
Employees 136
Stock Exchange NASDAQ
Ticker Symbol ANAB
Full Company Profile

Financial Performance

In 2024, AnaptysBio's revenue was $91.28 million, an increase of 432.03% compared to the previous year's $17.16 million. Losses were -$145.23 million, -11.24% less than in 2023.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price target is $48.0, which is an increase of 133.12% from the latest price.

Price Target
$48.0
(133.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

6 days ago - GlobeNewsWire

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

27 days ago - GlobeNewsWire

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant ...

3 months ago - Seeking Alpha

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also b...

3 months ago - Seeking Alpha

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

AnaptysBio, Inc. ANAB on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.

3 months ago - Benzinga

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that inve...

3 months ago - GlobeNewsWire

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call...

3 months ago - GlobeNewsWire

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial r...

4 months ago - GlobeNewsWire

Anaptys Announces Stock Repurchase Plan

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...

5 months ago - GlobeNewsWire

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and t...

6 months ago - GlobeNewsWire

Anaptys Announces Participation in March Investor Conferences

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

6 months ago - GlobeNewsWire

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endp...

7 months ago - GlobeNewsWire

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor cal...

7 months ago - GlobeNewsWire

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

7 months ago - GlobeNewsWire

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license...

7 months ago - GlobeNewsWire

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

8 months ago - GlobeNewsWire

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monot...

9 months ago - Benzinga

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 4...

9 months ago - Reuters

AnaptysBio abandons eczema drug development after mid-stage trial failure

AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.

9 months ago - Reuters

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that inve...

9 months ago - GlobeNewsWire

Anaptys Announces Participation in November and December Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...

10 months ago - GlobeNewsWire

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

10 months ago - GlobeNewsWire

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis ...

1 year ago - Seeking Alpha

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from addition...

1 year ago - GlobeNewsWire

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

1 year ago - GlobeNewsWire